afegostat tartrate
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2007 (NCT00433147)
Timeline
Indications
Studied for
Mechanism of action
- Beta-glucocerebrosidaseSTABILISER
GBA stabiliser
Specifically and reversibly binds GBA (GCase) in the ER with high affinity; this stabilizes the active form of the enzyme in the ER and increases trafficking of GBA to lysosomes
Chemistry & pharmacology
Loading structure…
SMILES
O=C(O)C(O)C(O)C(=O)O.OC[C@H]1CNC[C@@H](O)[C@@H]1O- Mol. weight
- 297.26 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2105671 ↗
Also known as
- afegostat tartrate
- afegostat tartrate
- at2101
- at2101
- at-2101
- at-2101
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00875160 | Phase 1 | Apr 1, 2009 | Amicus Therapeutics |
| NCT00813865 | Phase 2 | Jan 1, 2009 | Amicus Therapeutics |
| NCT00446550 | Phase 2 | Dec 1, 2007 | Amicus Therapeutics |
| NCT00433147 | Phase 2 | Feb 1, 2007 | Amicus Therapeutics |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Amicus Therapeutics | For profit | 4 | 4 | 2 | 2007 |
1 organizations
Page 1 / 1